Human Amniotic Membrane (hAM) for Stage II Maxillomandibu... | NCT05664815

NCT05664815

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Description Module

Detailed Description

Medication-Related Osteonecrosis of the Jaw (MRONJ) is a complication of taking anti-tumor (anti-angiogenic) and bone anti-resorptive treatments (biphosphonates, Denosumab) which impact bone healing and renewal capacities, which can lead to bone necrosis. It affects 1 to 10% of patients and is classified into 4 stages.

There is no reference document for their management, which requires antibiotics, local antiseptics and tissue debridement sometimes associated with sequestrectomy. The objective of treatment is very often to obtain healing of the oral mucosa to cover the exposed bone. Without treatment, stage II MRONJ can progress to stage III, with orostoma, pathological fractures and extra-fistula.

The human amniotic membrane (hAM) has poor (even no) immunogenicity and exerts an anti-inflammatory, anti-fibrotic, antimicrobial, antiviral and analgesic effect. It is a source of multipotent stem cells and growth factors that promote tissue regeneration.

A pioneering, non-comparative study reports the use of hAM in MRONJ with very encouraging results in terms of re-epithelialization, absence of pain and infection (Ragazzo 2018). Recently, the same team published a retrospective study where 49 patients (stage 1 to 3) were included, including 27 treated with hAM (Ragazzo 2021). They report a significant improvement in quality of life and pain in the treated group.

hAM would provide a new approach in the treatment of stage II MRONJ by acting on: the quality and speed of mucosal healing, pain, even infection and regeneration of the underlying bone.

This study aims to demonstrate, during the first standard surgical management of patients with stage II MRONJ, the effect of the implantation of a cryopreserved hAM on the maxillomandibular bone, on the healing of the oral mucosa three months after the operation.

In second objectives will be evaluated: pain, complications at the site of healing of the mucosa (erythema, abscess, purulent discharge, diffuse infection of soft tissues (cellulitis), orostoma, suborbital abscess, mandibular fracture), oral health -dental/quality of life and new bone formation at subsequent visits.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Application of human amniotic membrane (hAM)	Experimental	After conventional/standard treatment, hAM will be applied in a single layer against the bone defect before closure.	Biological: Human Amniotic Membrane
Conventional/standard treatment	Active Comparator	Conventional/standard surgery.	Other: Conventional/Standard treatment

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Human Amniotic Membrane	Biological	After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges. With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone. For closure after hAM grafting : 2 options are possible: Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of patients with re-apparition of bone exposure	Number of patients with re-apparition of bone exposure visually observed by the surgeon. Clinical examination: reopening of the scar / reappearance of exposed bone / taking a photograph of the treated area	Between Day 1 post-surgery and Month 3 post-surgery

Secondary Outcomes

Measure	Description	Time Frame
Number of patient with re-opening of the scar / reappearance of the bone exposure added visually during the control visit	Re-apparition of bone exposure visually observed by the surgeon. Clinical examination: reopening of the scar / reappearance of exposed bone / taking a photograph of the treated area	Day 0 (the day of the surgery) or Day 1 post-surgery

Eligibility Module

Eligibility Criteria

INCLUSION CRITERIA

Men and women over the age of 18
Patient treated in the context of a tumor pathology during which he received treatment with bisphosphonates, Denosumab or anti-angiogenics, and/or, very often, switch of treatment or combination. Current treatment or mention of treatment in patient history
MRONJ stage II certified clinically and radiologically. Also in the maxilla, stage II MRONJ without bucco-sinus communication after excision of the necrotic bone. Similarly, if a tooth with antral roots must be extracted and creates a bucco-sinus communication, if a MRONJ results, it will be stage II
Patients with stage II MRONJ of childbearing age with current contraception or patients already postmenopausal
Signature of the informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study, that he agrees to participate in the study as well as to comply with the requirements and restrictions inherent in this study
Affiliation to a French social security scheme or beneficiary of such a scheme

NON-INCLUSION CRITERIA

Life expectancy of less than 6 months assessed by oncologists
Existence of an evolving cervico-facial neoplasia or an evolving oral neoplastic process informed by oncologists
History of oral and/or cervico-facial radiotherapy
Allergy to one of these two antibiotics: amoxicillin-clavulanic acid or clindamycin-metronidazole combination
Patient contraindicated for surgery due to his state of health, with general anesthesia or local anesthesia.
MRONJ stage I and stage III
Stage II MRONJ in patients with only osteoporosis
Patients receiving treatments that may affect bone and/or mucous tissue as well as their metabolism: Patients on long-term corticosteroid therapy or immunosuppressants
Patients with other diseases that may affect bone and/or mucous tissue as well as their metabolism: Bone diseases (such as brittle bone disease or Osteogenesis imperfecta, primary bone tumors in the maxilla or mandible (osteosarcoma, sarcoma, rhabdomyosarcoma ,…), any other malignant bone tumour; metabolic diseases with bone repercussions (Paget's disease, osteomalacia,…)
Patients of childbearing age without contraception
Legal incapacity or limited legal capacity
Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator
Subject not affiliated to a social security scheme
Patient under guardianship, curatorship or imprisonment
Patient who notified his refusal to participate in the research
Patient who participates in another clinical research

EXCLUSION CRITERIA

During surgery: Discovery of an interrupting MRONJ with damage to the basilar edge (which corresponds to stage III).
During surgery: Following a sequestrectomy discovery of spontaneous or ongoing healing.
During the inclusion period: Patient to benefit from invasive "dental" surgeries directly related to bone exposure and in conjunction with taking risky molecules (factors favoring the occurrence of MRONJ): dental avulsions, curettage apical granulomas or cysts, endodontic treatments, or alveolar bone procedure (regularization of ridges).
During the inclusion period: Patient with metastases all over the mandible.
During the inclusion period: State of health of the patient which deteriorates due to his cancer during the inclusion period.

ID	Term
C030910	cancer procoagulant
D003226	Congresses as Topic

ID	Term
D009938	Organizations
D004472	Health Care Economics and Organizations